Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors. Tissue Antigens 2007 Apr;69 Suppl 1:25-30
Date
04/21/2007Pubmed ID
17445158DOI
10.1111/j.1399-0039.2006.759_2.xScopus ID
2-s2.0-34247259667 (requires institutional sign-in at Scopus site) 58 CitationsAbstract
The application of unrelated donor hematopoietic cell transplantation can be expanded with the use of mismatched donors if human leukocyte antigen (HLA) disparity does not lead to increased morbidity and mortality. The rules that govern permissibility of HLA mismatches are not well defined. The International Histocompatibility Working Group in hematopoietic cell transplantation measured the risks associated with locus-specific disparity in 4796 patients transplanted for low, intermediate, or high-risk hematologic diseases. The permissibility of a given HLA mismatch is in part defined by the locus and by disease risk.
Author List
Petersdorf EW, Gooley T, Malkki M, Horowitz M, International Histocompatibility Working Group in Hematopoietic Cell TransplantationAuthor
Mary M. Horowitz MD, MS Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAdult
Aged
Blood Donors
Child
Child, Preschool
Donor Selection
Female
Graft Survival
Graft vs Host Disease
HLA Antigens
Haplotypes
Hematologic Neoplasms
Hematopoietic Stem Cell Transplantation
Histocompatibility Testing
Humans
Infant
Male
Middle Aged
Transplantation
Treatment Outcome
